Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum SCYNEXIS Inc SCYX

Healthcare Biotechnology
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens,... see more

Bullboard (NDAQ:SCYX)

View:
1 2 3 Next
Comment by JonathanJSmithon Mar 31, 2023 9:34am

RE:RE:wtf?

They sold the drug, not the company. Too bad, I wish they had sold the entire company.  I guess this useless management team gets to keep its jobs for the time being. If someone was lucky to get ...more  
114
Discussion
Comment by Iseneschalon Mar 30, 2023 11:52am

RE:wtf?

Great timing Mr. Smith...... Care to stick your other foot in your mouth?? Don't quit ur day job !
81
Discussion
Post by JonathanJSmithon Mar 16, 2023 11:49am

wtf?

What happened to these guys? What a disgrace. Fire the entire management team and start anew. Sell this company for what can be salvaged.  I can't believe how wrong I was with this one. Oh ...more  
206
Discussion
Post by JonathanJSmithon Aug 02, 2022 8:23am

Can we expect additional Rx's to the fold this winter?

It's been a while and I've had some time to digest several variables; here are some of my findings: These guys are still trading well below cash, which is interesting. According to their most ...more  
241
Comment by JonathanJSmithon Apr 26, 2022 8:33am

RE:RE:RE:RE:BREXAFEMME - published User side effects

I'm disgusted too. What does $45MM get them, another quarter's worth of financing - maybe two? One would think that they'd do a financing AFTER their sNDA submittal. I guess they ...more  
175
Discussion
Comment by dmacdon Apr 22, 2022 4:48pm

RE:RE:RE:BREXAFEMME - published User side effects

I was going to sell at a loss, but decided to lower my average cost due to the discount. They will have $150M cash less Q1 spend. Probably trading at 70% current cash with an approved blockbuster drug ...more  
138
Discussion
Comment by JonathanJSmithon Mar 31, 2022 12:33pm

RE:RE:BREXAFEMME - published User side effects

Yeah, I agree - worse sales than I had expected. They should get a pop however when they submit their supplemental NDA vis-a-vis rVVC in Q2. I'm still holding as their MC is hovering around cash ...more  
118
Discussion
Comment by dmacdon Mar 29, 2022 11:39am

RE:BREXAFEMME - published User side effects

The problem is Mario and Christine are spending with reckless abandon. We need a businessman to run the company not a doctor. Mario can raise money but it dilutes so value is not delivered. Burry will ...more  
108
Discussion
Post by GMA133on Feb 07, 2022 3:22pm

BREXAFEMME - published User side effects

Join me by taking your action by contacting SCYX Investor Relations.   Today, I emailed Irina of SCYX - Investor Relations & recommended that Marco Taglietti, M.D.  launch a ...more  
193
Discussion
Comment by dmacdon Jan 21, 2022 3:35pm

RE:RE:RE:RE:RE:Stop Raising Dilutive Funds

Valued at cash again... well plus the long term debt. Expecting $20M burn as sales will take a while. Question is can they avoid another dilution with profits within next 3 or 4 quarters. The new ...more  
124
Discussion
Comment by JonathanJSmithon Dec 06, 2021 3:16pm

RE:RE:RE:RE:Stop Raising Dilutive Funds

Good presentation today. Also, good to hear that Burry bought almost 800K shares recently. Ibrexa will be a billion+ dollar drug within a few short years; it'll be quite a lucrative franchise as ...more  
102
Discussion
Comment by dmacdon Nov 19, 2021 4:48pm

RE:RE:RE:Stop Raising Dilutive Funds

Good volume. Back to breakeven. The payoff has taken a while but it'll be worth it. Very tight share structure.
102
Discussion
Comment by dmacdon Nov 16, 2021 9:55am

RE:RE:RE:Stop Raising Dilutive Funds

https://www.reuters.com/business/finance/big-short-burry-exits-bearish-bets-tesla-google-2021-11-16/ From the CEO BBs
77
Discussion
Comment by dmacdon Nov 15, 2021 11:22pm

RE:RE:Stop Raising Dilutive Funds

Good points. I have accumulated about my limit for these speculative buy mostly derisked value stocks. I plan to hold tight for 3 to 5 years and hope management will value the SP. Thanks!
75
Discussion
Comment by JonathanJSmithon Sep 20, 2021 8:55am

RE:Stop Raising Dilutive Funds

There's no real capital raise here or dilution (only ~1.3mm shares). They filed the recent S3/prospectuses for a couple of purposes - because the original (written 3 years ago) was expiring, and ...more  
103
Discussion
1 2 3 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities